Compared to traditional formulations, solid-lipid nanoparticles (SLNs) are a novel type of nanosystems that are used to deliver medication to specific sites more effectively and bioavailablely. SLNs are easier to biodegrade, less toxic, and have less negative consequences. They are also more biocompatible. Drugs that are hydrophilic, hydrophobic, or lipophilic can be added to SLNs to improve their chemical and physical stability in harsh conditions. Incorporating poorly soluble medicines, biologicals, proteins, and other anti helminthic agents into solid-lipid nanoparticles (SLNs) can improve their therapeutic efficacy, bioavailability, and target specificity. Anti helminthic medications based on SLNs are now effective against severe helmenthic infections that are resistant to drugs. A special focus on helminthic infections is placed on the importance of SLNs in the delivery of classical anti helminthic drugs, as well as their preparation, physicochemical characteristics, structure, and sizes, composition, and drug entrapment efficacy.